Eisai Co Ltd (4523.T) Quote| Reuters.com
Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

5,724JPY
10:18pm EDT
Change (% chg)

¥36 (+0.63%)
Prev Close
¥5,688
Open
¥5,716
Day's High
¥5,774
Day's Low
¥5,702
Volume
568,700
Avg. Vol
1,011,566
52-wk High
¥8,996
52-wk Low
¥5,383

4523.T

Chart for 4523.T

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South... (more)

Overall

Beta: 0.52
Market Cap(Mil.): ¥1,759,828.00
Shares Outstanding(Mil.): 296.57
Dividend: 70.00
Yield (%): 2.53

Financials

  4523.T Industry Sector
P/E (TTM): 30.94 34.76 35.71
EPS (TTM): 191.77 -- --
ROI: 6.64 15.00 14.23
ROE: 9.37 16.06 15.43

BRIEF-U.S. FDA expands approval of Eisai's cancer drug Lenvima

* FDA Approves Eisai's Lenvima (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic therapy Source text for Eikon: (Bengaluru Newsroom: +1 646 223 8780)

May 13 2016

BRIEF-Eisai signed cooperation agreements with Pharmstandard

* Co, Pharmstandard signed cooperation agreements relating to localised production of Eisai products in Russia Source text for Eikon: Further company coverage: (Reporting by Vishal Sridhar)

Apr 05 2016

FDA approves Eisai's drug Halaven for type of soft tissue cancer

The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer.

Jan 29 2016

CORRECTED-FDA approves Eisai's drug Halaven for type of soft tissue cancer (Jan. 28)

Jan 28 The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer.

Jan 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.